MK-2206 window of opportunity study in breast cancer

被引：6
作者：
Akcakanat, Argun [1 ]
Meric-Bernstam, Funda [1 ,2 ,3 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Al Nahyan Inst Personali, Houston, TX 77030 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷
关键词：
AKT INHIBITOR MK-2206; TRIAL; BIOMARKERS; PTEN;
D O I：
10.21037/atm.2018.10.32
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 12 条
  • [1] SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
    Gonzalez-Angulo, Ana M.
    Krop, Ian
    Akcakanat, Argun
    Chen, Huiqin
    Liu, Shuying
    Li, Yisheng
    Culotta, Kirk S.
    Tarco, Emily
    Piha-Paul, Sarina
    Moulder-Thompson, Stacy
    Velez-Bravo, Vivianne
    Sahin, Aysegul A.
    Doyle, Laurence A.
    Do, Kim-Anh
    Winer, Eric P.
    Mills, Gordon B.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (03):
  • [2] Kalinsky K, 2018, CLIN TRANSL ONCOL
  • [3] A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
    Litton, J. K.
    Scoggins, M.
    Ramirez, D. L.
    Murthy, R. K.
    Whitman, G. J.
    Hess, K. R.
    Adrada, B. E.
    Moulder, S. L.
    Barcenas, C. H.
    Valero, V.
    Gomez, J. Schwartz
    Mittendorf, E. A.
    Thompson, A.
    Helgason, T.
    Mills, G. B.
    Piwnica-Worms, H.
    Arun, B. K.
    [J]. NPJ BREAST CANCER, 2017, 3
  • [4] A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
    Ma, Cynthia X.
    Suman, Vera
    Goetz, Matthew P.
    Northfelt, Donald
    Burkard, Mark E.
    Ademuyiwa, Foluso
    Naughton, Michael
    Margenthaler, Julie
    Aft, Rebecca
    Gray, Richard
    Tevaarwerk, Amye
    Wilke, Lee
    Haddad, Tufia
    Moynihan, Timothy
    Loprinzi, Charles
    Hieken, Tina
    Barnell, Erica K.
    Skidmore, Zachary L.
    Feng, Yan-Yang
    Krysiak, Kilannin
    Hoog, Jeremy
    Guo, Zhanfang
    Nehring, Leslie
    Wisinski, Kari B.
    Mardis, Elaine
    Hagemann, Ian S.
    Vij, Kiran
    Sanati, Souzan
    Al-Kateb, Hussam
    Griffith, Obi L.
    Griffith, Malachi
    Doyle, Laurence
    Erlichman, Charles
    Ellis, Matthew J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6823 - 6832
  • [5] Designs of preoperative biomarkers trials in oncology: a systematic review of the literature
    Marous, M.
    Bieche, I.
    Paoletti, X.
    Alt, M.
    Razak, A. R. A.
    Stathis, A.
    Kamal, M.
    Le Tourneau, C.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2419 - 2428
  • [6] Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer
    Maugeri-Sacca, Marcello
    Barba, Maddalena
    Vici, Patrizia
    Pizzuti, Laura
    Sergi, Domenico
    Catenaro, Teresa
    Di Lauro, Luigi
    Mottolese, Marcella
    Santini, Daniele
    Milella, Michele
    De Maria, Ruggero
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 132 - 142
  • [7] Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
    Saal, Lao H.
    Johansson, Peter
    Holm, Karolina
    Gruvberger-Saal, Sofia K.
    She, Qing-Bai
    Maurer, Matthew
    Koujak, Susan
    Ferrando, Adolfo A.
    Malmstrom, Per
    Memeo, Lorenzo
    Isola, Jorma
    Bendahl, Par-Ola
    Rosen, Neal
    Hibshoosh, Hanina
    Ringner, Markus
    Borg, Ake
    Parsons, Ramon
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (18) : 7564 - 7569
  • [8] Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
    Sangai, Takafumi
    Akcakanat, Argun
    Chen, Huiqin
    Tarco, Emily
    Wu, Yun
    Do, Kim-Anh
    Miller, Todd W.
    Arteaga, Carlos L.
    Mills, Gordon B.
    Gonzalez-Angulo, Ana Maria
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5816 - 5828
  • [9] Window of opportunity studies: Do they fulfil our expectations?
    Schmitz, Sandra
    Duhoux, Francois
    Machiels, Jean-Pascal
    [J]. CANCER TREATMENT REVIEWS, 2016, 43 : 50 - 57
  • [10] Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Stemke-Hale, Katherine
    Gonzalez-Angulo, Ana Maria
    Lluch, Ana
    Neve, Richard M.
    Kuo, Wen-Lin
    Davies, Michael
    Carey, Mark
    Hu, Zhi
    Guan, Yinghui
    Sahin, Aysegul
    Symmans, W. Fraser
    Pusztai, Lajos
    Nolden, Laura K.
    Horlings, Hugo
    Berns, Katrien
    Hung, Mien-Chie
    van de Vijver, Marc J.
    Valero, Vicente
    Gray, Joe W.
    Bernards, Rene
    Mills, Gordon B.
    Hennessy, Bryan T.
    [J]. CANCER RESEARCH, 2008, 68 (15) : 6084 - 6091
12